320 related articles for article (PubMed ID: 26945543)
21. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.
Liao YP; Jiang JL; Zou WY; Xu DR; Li J
World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880
[TBL] [Abstract][Full Text] [Related]
22. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
23. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients.
Chen G; Liu H; Hu ZQ; Bai JH; Liu QY; Zhao YP; Gan XM; Wang F; Wang DD; Ma LJ; Li L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):901-6. PubMed ID: 26011237
[TBL] [Abstract][Full Text] [Related]
24. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study.
Wang Y; Luo XM; Yang D; Zhang J; Zhuo HY; Zhang J; Jiang Y
World J Gastroenterol; 2013 Feb; 19(6):923-30. PubMed ID: 23429298
[TBL] [Abstract][Full Text] [Related]
25. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
26. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
27. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
[TBL] [Abstract][Full Text] [Related]
28. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
29. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
[TBL] [Abstract][Full Text] [Related]
31. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
[TBL] [Abstract][Full Text] [Related]
32. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management.
Lubel JS; Angus PW
J Gastroenterol Hepatol; 2010 May; 25(5):864-71. PubMed ID: 20546439
[TBL] [Abstract][Full Text] [Related]
34. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
35. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
37. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
38. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation.
Chen YC; Chuang MK; Chou NK; Chi NH; Wu IH; Chen YS; Yu HY; Huang SC; Wang CH; Tsao CI; Ko WJ; Wang SS
Transplant Proc; 2012 May; 44(4):910-2. PubMed ID: 22564582
[TBL] [Abstract][Full Text] [Related]
39. Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy.
Cheung WI; Lin SY; Leung VK; Fung KS; Lam YK; Lo FH; Chau TN
Hong Kong Med J; 2011 Oct; 17(5):376-80. PubMed ID: 21979474
[TBL] [Abstract][Full Text] [Related]
40. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
